Výsledky vyhledávání - "Ayako Shiraishi"

Akademický článek

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

Autor: Nagahide Takahashi, Aya Yamada, Ayako Shiraishi, Hiroko Shimizu, Ryosuke Goto, Yushin Tominaga

Publikováno v: BMC Psychiatry, Vol 21, Iss 1, Pp 1-13 (2021)

Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of e

Externí odkaz: https://doaj.org/article/02f051ae23cc4aadb841d632bc961c7d

Zobrazit plný text záznamu

Akademický článek

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Autor: Maarten Timmers, Johannes Rolf Streffer, Alberto Russu, Yushin Tominaga, Hiroko Shimizu, Ayako Shiraishi, Kanaka Tatikola, Pascale Smekens, Anne Börjesson-Hanson, Niels Andreasen, Jorge Matias-Guiu, Miquel Baquero, Mercè Boada, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs

Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)

Abstract Background β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known

Externí odkaz: https://doaj.org/article/29adc1da679f4c53b4ec494c0c1dcf5e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

Autor: Ryosuke Goto, Yushin Tominaga, Hiroko Shimizu, Nagahide Takahashi, Aya Yamada, Ayako Shiraishi

Publikováno v: BMC Psychiatry
BMC Psychiatry, Vol 21, Iss 1, Pp 1-13 (2021)

Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::706f79dd9acce89daa01f060dfa4e546
http://europepmc.org/articles/PMC8547110

Zobrazit plný text záznamu

Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid treated rats

Autor: Ayako Shiraishi, Masashi Fujii, Chie Sato, Kentaro Ohuchi, Yoichi Shimada, Toyohito Segawa, Naohisa Miyakoshi, Yuji Kasukawa, Sadaoki Sakai, Hayato Kinoshita

Publikováno v: Journal of Bone and Mineral Metabolism. 34(2):171-178

Glucocorticoid causes secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D3 analog, eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats and determined th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61189587418b80546b87cc92a7b27bc5
http://hdl.handle.net/10295/00003438

Zobrazit plný text záznamu

JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling

Autor: Hideto Kameda, Takashi Nishina, Takaharu Katagiri, Hiroyasu Nakano, Soh Yamazaki, Shogo Endo, Soichiro Kimura, Hideki Sumimoto, Kazuhiro Tateda, Hideo Yagita, Ayako Shiraishi, Yuto Fukui, Tetuo Mikami, Sayaka Katagiri, Kotaro Aoki

Publikováno v: Mucosal immunology. 12(5)

The AP-1 transcription factor JunB plays crucial roles in multiple biological processes, including placental formation and bone homeostasis. We recently reported that JunB is essential for development of Th17 cells, and thus Junb-deficient mice are r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b00d54c86d4b78566bd4967146cfda
https://pubmed.ncbi.nlm.nih.gov/31285535

Zobrazit plný text záznamu

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease

Autor: Pascale Smekens, Niels Andreasen, Mercè Boada, Yushin Tominaga, Luc Van Nueten, Alberto Russu, Jorge Matías-Guiu, Miquel Baquero, Sebastiaan Engelborghs, Ina Tesseur, Johannes Streffer, Ayako Shiraishi, Kanaka Tatikola, Hiroko Shimizu, Luc Tritsmans, Maarten Timmers, Anne Börjesson-Hanson

Publikováno v: Alzheimers Research & Therapy
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-18 (2018)
Alzheimer's research & therapy
Alzheimer's Research & Therapy

Background β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known as JNJ-5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a6297d9eaeedbe80ecf85135b8bd35
https://doi.org/10.1186/s13195-018-0415-6

Zobrazit plný text záznamu

Alfacalcidol Inhibits Bone Resorption and Stimulates Formation in an Ovariectomized Rat Model of Osteoporosis: Distinct Actions from Estrogen

Autor: Satoshi Takeda, Toshio Matsumoto, Ayako Shiraishi, Etsuro Ogata, Toshitaka Nakamura, Toshimi Masaki, Kyoji Ikeda, Yasushi Uchiyama, Yoshinobu Higuchi, Noboru Kubodera, K. Sato

Publikováno v: Journal of Bone and Mineral Research. 15:770-779

Although alfacalcidol has been widely used for the treatment of osteoporosis in certain countries, its mechanism of action in bone, especially in the vitamin D-replete state, remains unclear. Here we provide histomorphometric as well as biochemical e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0455dd12405cda4a8ca7b73449e08330
https://doi.org/10.1359/jbmr.2000.15.4.770

Zobrazit plný text záznamu

1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression

Autor: Hironori Kaneko, Tadatsugu Taniguchi, Yoshiaki Toyama, Takeshi Miyamoto, Yoshiteru Miyauchi, Ayako Shiraishi, Akio Tanaka, Toshio Suda, Kenichiro Matsuzaki, Sadaoki Sakai, Mitsuru Furukawa, Keiji Saito, Hironari Takaishi

Publikováno v: Journal of Bone and Mineral Metabolism. 27:643-652

1-Alpha, 25-dihydroxy vitamin D(3) (1alpha,25(OH)(2)D(3)), an active form of vitamin D(3), plays a critical role in calcium and bone metabolism. Although 1alpha,25(OH)(2)D(3) has been used for osteoporosis therapy, the direct role of 1alpha,25(OH)(2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4339764dc9001f99a77e9cc8d8b470
https://doi.org/10.1007/s00774-009-0084-4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání